Adjuvant chemotherapy for breast cancer and cognitive impairment

Southern Medical Journal

Volumn 102, Issue 9, 2009, Pages 929-934

  Marín, Álvaro Pinto ^a,b   Sánchez, Andrés Redondo ^a   Arranz, Enrique Espinosa ^a   Auñón, Pilar Zamora ^a   Barón, Manuel González ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemobrain; Cognitive impairment; Long term survivors

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; COGNITION; DEPRESSION; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MEMORY DISORDER; MENTAL CONCENTRATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR; WECHSLER MEMORY SCALE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; SURVIVORS;

EID: 70349089069     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181b23bf5     Document Type: Review

References (45)

1. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70.
2. Castellon SA, Silverman DHS, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005;92:199-206.
3. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995;4:61-66.
4. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
5. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640-650.
6. Brezden CB, Philips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18: 2695-2701.
7. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-493.
8. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175-4183.
9. Wefel JS, Lenzi R, Theriault RL, et al. The cognitivie sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292-2299.
10. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organi-sation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
11. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003;95:190-197.
12. Maruff P, Falleti MG. Incidence of chemotherapy-related cognitive impairment threatened by inflated Type I error. Cancer 2004;101:2143-2144.
13. Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev 1995;16:35-62.
14. Singh M, Meyer EM, Millard WJ, et al. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994;644:305-312.
15. Honjo H, Tamura T, Matsumoto Y, et al. Estrogen as a growth factor to central nervous cells. Estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber. J Steroid Biochem Mol Biol 1992;41:633-635.
16. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994;29:431-436.
17. Matsumoto A. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology 1991;16:25-40.
18. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895-1906.
19. Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990;14:26-43.
20. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-2217.
21. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-2641.
22. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
23. Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression and dependence in activities of daily living in elderly nursing home residents. Women Health 2000;31:71-85.
24. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165-176.
25. Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004;13:61-66.
26. Matsuda T, Takayama T, Tashiro M, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005;12:279-287.
27. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995;12:231-235.
28. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res 2001;50:86-94.
29. Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol 2004;5:273-282.
30. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004;28:7-18.
31. Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 2002; 95:2017-2026.
32. Bruera E, Fainsinger RL, Miller MJ, et al. The assessment of pain intensity in patients with cognitive failure: a preliminary report. J Pain Symptom Manage 1992;7:267-270.
33. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 2002;3(suppl 3):S84-S90.
34. Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer 2006;14:1111-1118.
35. Fogel BS. The high sensitivity cognitive screen. Int Psychogeriatr 1991; 3:273-288.
36. Collie A, Maruff P, Darby DG, et al. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419-428.
37. Erlanger D, Feldman D, Kutner K, et al. Development and validation of a web-based neuropsychological test protocol for sports-related return-to-play decision-making. Arch Clin Neuropsychol 2003;18:293-316.
38. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cer-ebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103:303-311.
39. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neurosychological, pathophysiological and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003;8:201-216.
40. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain grey and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109:146-156.
41. Berglund G, Bolund C, Fornander T, et al. Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 1991;27:1075-1081.
42. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002;13:1387-1397.
43. Taillibert S, Voillery D, Bernard-Marty C. Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007;19:623-627.
44. Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008;16:577-583.
45. Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-629.